UNSPSC 51371506: Doxpicomine hydrochloride

This classification denotes an analgesic agent with the molecular formula C12H18N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 27DYG0QPCR, chemically known as 3-pyridinemethylamine, alpha-1,3-dioxan-5-yl-n,n-dimethyl-, monohydrochloride, (-)- but more generally known as doxpicomine hydrochloride, which bears US NIH Compound Identifier 71979. Most nations, for tariff and trade purposes, schedule doxpicomine hydrochloride under HS 29349990 and SITC 51579.

As of Q4 2014, DOXPICOMINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)[C@@H](C1CCCNC1)C2COCOC2.CL.

UNSPSC 51371506 Doxpicomine hydrochloride is a Commodity code that state and local governments use to procure prescription pharmaceuticals and related medications as part of public health, pharmacy benefit, and emergency response initiatives. In practice, the code captures procurement of naloxone, generic multi-source pharmaceuticals, over-the-counter products, and pharmaceutical supply chain services used by health departments, community health programs, and state pharmacy benefit managers to support patient care and opioid response efforts. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances representing multiple jurisdictions. Seminole County, Florida and the Texas Health and Human Services Commission and Minnesota Department of Administration have all issued solicitations under or related to this code in the past year, indicating activity from both individual counties and statewide coordinating entities.

Recent solicitations show the code encompasses both direct product procurement and supply chain architecture. Seminole County issued IFB 60459723LAS (due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, a two-year contract with one-year renewal option, with FEMA potential funding and federal compliance requirements. The Texas HHS Commission posted RFI HHS0017013 (April 3, 2026) to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager channels, signaling state-level procurement rethinking. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 (due March 26, 2026) to establish contracts for generic pharmaceuticals and OTC products distributed across MMCAP's multistate membership including Oregon, with authorized-wholesaler distribution, cGMP and DSCSA compliance requirements, and pricing weighted 75 percent on competitiveness. Geographic activity includes Florida, Texas, Minnesota, and Oregon; contract terms run two to three years with optional extensions, and vendors must carry commercial general liability insurance of at least $5,000,000 per occurrence and maintain FDA compliance.